Journal of Proteomics & Bioinformatics
Open Access

ReAL effort to integrate genotypes and phenotypes in clinical development

International Conference on Protein Engineering

October 26-28, 2015 Chicago, USA

Z John Gu

Renascions Corporation, USA

Posters-Accepted Abstracts: J Proteomics Bioinform

Abstract :

This presentation will provide an overview of Renascions Association Links (ReAL), an innovative approach to drug development during clinical stages. This technology is a unique translational platform that combines drug MOAs, pathway genetics, population genetics and clinical outcomes in order to link genotypic information to phenotypic outcomes in clinical trials. Through ReAL, clinical data are redistributed into genetically based subgroups and clinical outcomes (efficacy and or safety) in sub-populations are examined more closely in order to yield higher clinical efficiency. The integration of genomic technologies into clinical development is complex for example, it consists of biomarker discovery, retrospective validations, prospective validations, etc. Renascions offers the Renascions Association Links (ReAL) approach, a unique method based on its proprietary collections of data samples to generate sub-population distributions based on the genetics of drug MOA and allows pharmaceuticals to redistribute its clinical outcomes and reexamine its efficacy and side effects in each sub-group with ReAL distributions. ReAL has worked with a half dozen clinical programs and has proven that its applications are not limited by drug type or disease. With clear MOAs, ReAL has successfully improved clinical outcome by increasing efficacy and safety profiles in clinical trials. In this presentation, Renascions will share our experience and challenges and the future potential of using ReAL technologies.

Biography :

Email: ajg001@renascions.com